COVID-19 is here to stay. It is a virus. It will mutate. Addition better more accurate and efficient tests are always being produced that replace first to market. Experience in responding to this one only enables quicker response to future problems.

They had the meeting with NASDAQ and must have a path forward for meeting all short term requirements. In order to get a 180 day extension on share price they would have to show good faith in raising the share price - thus getting approval for the board to do a reverse split.

A reverse split early (way before the extension is up) would be foolish. They would be guaranteed stock price taking a dive. IMO they will get approval, but then see what happens with orders over the next 5 months. If sp does not rise above $1 in 5 months, then you will see the RS.

He mentioned a possibility of 4th quarter. The only possibilities that have worked for him is the word itself.

In which case, APDN must have plan for satisfying NASDAQ requirements other share price which can get a 180 day extension.

I’m surprised that we haven’t heard a word about NASDAQ mtg.

The only possible need for a reverse split is to maintain listing.

If company meets share holder $’s, then an extension for $/share is in order.

If not, company can let the delisting happen and just trudge on.

The main reason for maintains the listing is for access to $$$. If Dr is confident $’s will start flowing in, then let the stock delist and just realist at a later date.

Just need to realize that if NASDAQ is a bomb, it will not sink the ship. The ship will continue to sail, maybe thru a large dip, but at a much slower speed.

Short ton - long ton - doesn’t matter

Be nice to mark 100,000,000 lbs of feathers

Gotta work on your math conversions friend.

50k tons is 110 million pounds

Receipt of Delisting Notice posted to SEC

Mick is right. It’s probably very similar to home marking and car marking kits.

It’s a means of creating continued interest.

Should be announcing receipt of TheraCann’s 2nd of 3 payments ($2M) soon

Can’t expect money attached to TheraCann announcements unless it will be a significant move beyond a cummulative $5M with APDN for thier contract year..

Advertising “100% Egyptian Cotton” has been ubiquitous with a quality product. The fact that there has been many times more Egyptian Cotton material sold every year than what is harvested has been a long running joke.

Now, APDN has the testing ability that forces manufacturers to stand behind their advertising.

Shortly, if someone wants that 100% Egyptian Cotton, there will be ~80% less available.

So this is excellent news for Pima Cotton grown in the US

I don’t know why everyone is worried about a reverse split. A RS does not resolve both NASDAQ issues, only the stock price. And shareholder ownership shortcomings do not have the option for a 180-day extension.

Nobody wants the stock to be dropped by NASDAQ due to exposure to various index’s and Mutual Funds that could pick it up based on a positive media blitz and a couple of positive new business pr’s

There is no reason for a dollar announcement pertaining to tagging cannibis in China. Theracann Int subsidary: ETCH Bio Trace, has an exclusive Licensing and cooperation agreement with APDN for the GLOBAL legal cannibis and hemp markets.

See the March 29 announcement.

Thus, Theracann and CannAcubed entering into an agreement is just part of the existing agreement that is paying APDN a minimum of $5M (over 3 payments in 3rd and 4th quarter) this year.

The material, equipment, and other resources necessary to facilitate the CanAcubed work may or may not increase revenue from Theracann above $5M for 2019

And, I never saw any press as to who proved/verified that the Cotton Wellspun was using wasn’t 100% Egyptisn Cotton. This happened after APDN had started their cotton fiber typing program.

If you are referring to Egyptian, no.

Egyptian was part of a scandal that hit all major retailers dealing with Wellspun and The Cotton Egypt Association that actually certified the material as 100% Egyptian Cotton

People don’t understand that the safety associated with today’s announcement is huge from a pharmaceutical perspective.

A little down the road it will make the Israeli deal look like peanuts.

The funny thing about that - plant DNA in itself can be classified as organic provided the rift growing conditions (only organically certified fertilizers, etc)

It’s the chemicals APDN uses in processing of the plant DNA to get to short strand in bulk that makes it GMO.

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

Source: Edgar (US Regulatory)

Filed Pursuant to Rule 424(b)(5)
File No. 333-218158


PROSPECTUS SUPPLEMENT
(To Prospectus dated May 26, 2017)



5,500,000 SHARES OF COMMON STOCK

AND

WARRANTS TO PURCHASE 5,500,000 SHARES OF COMMON STOCK

We are offering up to 5,500,000 shares of our common stock and warrants to purchase up to 5,500,000 shares of our common stock (the “Warrants”) in a firm commitment underwritten public offering by Maxim Group LLC, the underwriter. The shares of common stock and the Warrants are being offered pursuant to this prospectus supplement and accompanying prospectus. The Warrants will be issued separately but must be purchased together with the common stock. The combined purchase price for each share of common stock and accompanying Warrant is $0.50. The Warrants will be exercisable beginning on the date of issuance (the “Initial Exercise Date”), at an exercise price of $0.50 per share and will expire on the five-year anniversary of the Initial Exercise Date. The Warrants include an adjustment provision that, subject to certain exceptions, reduces their exercise price if the Company issues common stock or common stock equivalents at a price lower than the then-current exercise price of the Warrants, subject to a minimum exercise price of $0.14 per share. We have also granted the underwriter a period of 45 days to purchase up to an additional 825,000 shares of common stock and/or 825,000 Warrants, which the underwriter may only exercise to cover over-allotments made in connection with this offering.

The aggregate market value of our outstanding shares of common stock held by non-affiliates was $32,872,711 based on 30,112,057 shares of common stock outstanding as of December 20, 2018, of which 26,725,781 shares are held by non-affiliates, and a per share price of $1.23 based on the closing sale price of our common stock on November 7, 2018. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public primary offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million. During the 12-month period prior to and including the date of this prospectus supplement, we did not offer any securities pursuant to General Instruction I.B.6 of Form S-3.

Our common stock is listed on The Nasdaq Capital Market under the symbol “APDN.” On December 19, 2018, the last reported sales price of our common stock on The Nasdaq Capital Market was $0.70 per share.

The purchase of the securities offered through this prospectus supplement involves a high degree of risk. You should consider carefully the risk factors beginning on page S-14 of this prospectus supplement, on page 5 of the accompanying base prospectus, and in the documents incorporated by reference into this prospectus supplement before purchasing any of the securities offered by this prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

And with the last financing round Doc tied up most of the patents as collateral, should the company dissolve. This way, he and the other investors could take the patents and start anew.

$0.50 and $2,750,000
That won’t last long.

PimaCott needs to be purchased at an annual volume due to annual crops

Strictly an extension of existing. They disposed of the same number of shares they acquired with the new date 5 years down the road. Thus, the original price does not change.

$1.66 premarket with an Ask of $1.71. What is going on

If everyone saw APDN as over valued at $1.15, I’d expect $1.12 would be overvalued as well

Yet 44+K shares traded hands today.

Someone must think it’s of value to be willing to pay $1.12+ per share, else the price would be lower.

I expect the cotton order is a pay as you use it which could extend a couple of years

If I were responsible for one of the most counterfeited drugs in the world, I wouldn’t want to advertise when I start using a taggant to catch counterfeiters. I would want to bust as many as possible which is done by not letting the world know when marking of the drug begins. I’d keep it secret as long as possible.

Myotarg is a drug that is applied via IV. I don’t see our product being added to an injectable drug.

Colorcon and ACG both serve products that are taken orally.

I can see APDN marking the vials for the drug product as well as the packaging

Park, you finally get it.

However, unless ever Colorcon DMF is for a specific drug, Colorcon would not be able to update the DMF to include APDN secret sauce.

Not sure the FDA would allow a DMF to specify “With and Without secret sauce”

What says that the DMF ACG updated is doe an APDN excipient?

It’s more a matter of how much cotton WAS marked and invoicing the customers for the juice used.

They only get orders for application systems. Juice is supplied and billed for when used. They monitor usage and discuss planned use so they can ship another drum prior to the existing drum of juice running out.

Ok, the last three paragraphs are copied from one of my submit taps.

Someone previously included info about DMFs or a link about DMFs: there is a possibility that APDN (with Colorcons help) requested a DMF File Number prior to submittal. If this was the case, Colorcon may have been able to submit their DMF or modified DMF the same time as APDN. That would be best case.



W

Before there were GMOs and antibiotics, there was a pretty good natural balance. With the advent of antibiotics, nature evolved alternates that were not affected and now we are dealing with super bugs that there are very few if any antibiotics that are effective.

With GMOs for cotton (corn and other food plants) how will nature evolve. That is the long term fear. With GMOs creating a higher density of cotton in the fields, something in nature may evolve to take advantage of it as a food source. Then as that is pushed out of the cotton fields - does it go after cotton clothes and sheets as a food source.

Question, are these irrational fears? Sort of like the first coal fired power plants and the pollution they put out - who would have thought it would lead to workers getting black lung in coal mines and then global warming (if you believe in global warming).

Wether a DMF is needed for juice supplied to ACG is dependent upon wether or not a different juice formulation is needed for stability within ACGs process. And wether or not that formulation was included in the existing DMF.

Also, don’t know how our product will be applied to capsules. Will it be mixed into the polymer prior to capsule formation, or spray applied post capsule formation?

It depends on wether or not the FDA deems this to be a minor change that only requires notification within a companies annual update for the applicable drug. With our product being GRAS, and the application is within the product coating at ppt to ppb levels, and its an oral application (not injectable) I think the FDA would not review immediately. Another words, it’s good to go once Colorcon’s DMF is accepted.

If the FDA deems it necessary to review this type of change, it could take 1 to 3 months.

I just don’t see the FDA requiring an immediate review since this does not affect the manufacturing of the bulk drug product, or the formulation of the individual pills. It only affects the coating of the pills.

Takes a little time to enter data into the electronic submittal and properly review it before hitting the send button. Don’t know if they wait for the snail mail approval before proceeding afterwards. Then you have to have the right personnel available for the submittal process also.

For the above, I’d add a business week.

FDA’s review is 2-3 weeks plus one week making it 3-4 weeks.